Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program

Onkologie

Volumn 27, Issue 2, 2004, Pages 150-154

  Steurer, M ^a   Spizzo, G ^a   Mitterer, M ^b   Gastl, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Krankenhaus Franz Tappeiner   (Italy)

Author keywords

Myeloma; Thalidomide: therapy, side effects

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; HUMAN; HYPOTENSION; MALE; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUROTOXICITY; RASH; RETROSPECTIVE STUDY; SOMNOLENCE; THROMBOSIS; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 2442565795     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076904     Document Type: Article

References (24)

1. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 1994;330:484-489.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
3. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
4. Mesters RM, Padro T, Steins M, Bieker R, Retzlaff S, Kessler T, Kienast J, Berdel WE: Angiogenesis in patients with hematologic malignancies. Onkologie 2001;24(suppl 5):75-80.
5. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-4323.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
8. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
9. Haslett PA, Corral LG, Albert M, Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892.
10. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-2950.
11. Kropff M, Lang N, Bisping G, Domine N, Inning G, Henrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel W, Kienast J: Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-616.
12. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T: Thalidomide in patients with advanced multiple myeloma: A study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002;3:185-192.
13. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-494.
14. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78:34-39.
15. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002;87:408-414.
16. Cavenagh JD, Oakervee H: Thalidomide in multiple myeloma: Current status and future prospects. Br J Haematol 2003;120:18-26.
17. Durie BG, Stepan D: Low dose thalidomide alone and in combination: Long term follow-up. Blood 2001;98:163(abstract 688).
18. Durie BG: Low-dose thalidomide in myeloma: Efficacy and biologic significance. Semin Oncol 2002;29(suppl 17):34-38.
19. Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK: Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma 2003;44:1147-1149.
20. Moehler TM, Schlenzka J, Kasper B, Neben K, Egerer G, Ho AD, Goldschmidt H: Low incidence of deep vein thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. Onkologie 2002;25(suppl 4): 216(abstract 762).
21. D'Andrea A, Ma X, Aste-Amezaga M, Paganin C, Trinchieri G: Stimulatory and inhibitory effects of interleukin(IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med 1995;181:537-546.
22. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-5161.
23. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667.
24. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15:1950-1961.